Welcome!

News Feed Item

IntelliCell BioSciences Announces That It Will Develop Investigational Clinical Protocol Studies for the Treatment of ALS With Dr. Manuel Trujillo

NEW YORK, NY -- (Marketwired) -- 03/24/14 -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a research collaboration with Dr. Manuel Trujillo, Clinical Psychiatry NYU Department of Psychiatry and Medical Director of the Amen Clinic, to use its unique approach to the harvest and use of autologous adipose derived stromal vascular fraction cells (SVFC) for clinical studies of ALS (Lou Gehrig's Disease).

IntelliCell BioSciences and Dr. Trujillo are developing joint investigational clinical study protocols with initial efforts focusing on the assessment and treatment of patients with ALS. The protocols will be conducted under an Investigational New Drug Application ultimately in order to develop substantial evidence of effectiveness that will meet the statutory new drug approval standards as part of Intellicell's efforts to bring scientific rigor to an area filled with anecdotal evidence. Dr. Trujillo's sister, who is afflicted with ALS has been treated as an individual patient with, among other therapies, SVFCs, and showed improvement. The next step is controlled clinical trials.

IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a tremendous honor for IntelliCell to work with Dr. Trujillo in the field of ALS. This is a terrible disease that afflicts many people, dramatically affecting their lives. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with ALS a new and better way to have significant improvement in their qualities of life. We at IntelliCell are excited to have this opportunity to work with the distinguished neuroscientist, Dr. Trujillo, and start investigational clinical studies."

According to Dr. Trujillo, Chief Psychiatrist at the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments using SVFCs is going to change the world for ALS patients. I am excited to be part of this moment in scientific history and start investigational clinical studies. I believe there is hope for my ALS patients that never existed before."

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

About ALS
Amyotrophic lateral sclerosis (ALS), often referred to as "Lou Gehrig's Disease," is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed.

ALS is one of the most common neuromuscular diseases worldwide, and people of all races and ethnic backgrounds are affected. One or two out of 100,000 people develop ALS each year. Amyotrophic lateral sclerosis affects approximately 30,000 Americans. ALS cases are estimated at 1.2-4.0 per 100,000 individuals in Caucasian populations with a lower rate in other ethnic populations. ALS most commonly strikes people between 40 and 60 years of age, but younger and older people can also develop the disease. Men are affected slightly more often than women.

About Dr. Manuel Trujillo
Manuel Trujillo, MD, chief psychiatrist at Amen Clinics in New York, is a distinguished clinician, academic administrator, and clinical services innovator and researcher who dedicated his professional life to improving clinical outcomes of psychiatric treatment.

Prior to joining Amen Clinics, Dr. Trujillo was Director of Psychiatry at New York University -- Bellevue Hospital Center from 1991-2008, after holding senior clinical and administrative positions at Columbia University College of Physicians and Surgeons and other Schools of Medicine in New York City. During his term at Bellevue, he developed numerous innovative clinical programs such as culturally competent programs for Asians and Hispanics, and directed the Department's extensive involvement in the psychological aftermath of September 11, including outreach efforts to victims, families, children, rescue workers, minorities and other at risk populations.

In addition to his work at Amen Clinics, Dr. Trujillo is a Clinical Professor of Psychiatry and Director, Program and Fellowship in Public Psychiatry at New York University School of Medicine. He is the recipient of many research and service grants designed to improve treatment outcomes of severe and persistent mental illness such as schizophrenia and bipolar disorders, as well as create culturally competent treatment services and integrate psychiatric and addiction services into primary care. His research has contributed to the development of New York state policies that provide optimum community care for seriously ill psychiatric patients. He has written and presented extensively on Short-Term Dynamic Psychotherapy and Cross-Cultural Psychiatry, among other topics. In the last five years Dr. Trujillo has developed an interest in bringing neuroimaging to the center of clinical psychiatry and is actively collaborating with pioneers in this field, such as Dr. Daniel Amen.

Dr. Trujillo received a Bachelor of Science degree and M.D. from Seville University Medical School, Seville, Spain and completed his residency in psychiatry at Albert Einstein College of Medicine, NY. He received a fellowship from the Psychoanalytic Medicine Program, Post Graduate Center for Mental Health in New York 1976, as well as a Fellowship in Research Training in Psychiatry from the State University of New York in 1978.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
(646) 576-8308

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, introduced two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a multip...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"The reason Tier 1 companies are coming to us is we're able to narrow the gap where custom applications need to be built. They provide a lot of services, like IBM has Watson, and they provide a lot of hardware but how do you bring it all together? Bringing it all together they have to build custom applications and that's the niche that we are able to help them with," explained Peter Jung, Product Leader at Pulzze Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2,...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...